Medicare adds cancer blood tests—but only for seniors 68 and up, at first
H.R. 842 — Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act · Filed by Jodey Arrington (R-TX) · 338 cosponsors · Introduced Jan 31, 2025 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends Medicare to cover multi-cancer early detection screening tests (blood tests that screen for multiple cancer types at once) starting January 1, 2028. Medicare will pay for these tests using the same reimbursement rate as existing stool-based DNA screening tests, with age-based eligibility starting at 68 and increasing by one year annually, and a limit of one test per individual per year. The bill requires FDA clearance or approval and CMS determination that the test is 'reasonable and necessary,' and exempts tests rated A or B by the U.S. Preventive Services Task Force from age and frequency limits.
Why we flagged it
The bill's core function is straightforward: it adds a new covered service to Medicare with defined payment rates and eligibility rules. The named-after-person framing (Nancy Gardner Sewell) is commemorative but does not alter the bill's substantive mechanism, which is a standard coverage amendment.
What the text implies
- CMS retains sole discretion to determine whether a test is 'reasonable and necessary' without explicit clinical-evidence thresholds in the statute, creating regulatory uncertainty and potential for inconsistent coverage decisions across test manufacturers.
- The phased age-eligibility ramp (68 in 2028, 69 in 2029, etc.) creates a multi-year period where younger seniors (65–67) are excluded despite potentially benefiting from early cancer detection, raising equity questions about why age-based rationing was chosen over risk-based or universal eligibility.
The full analysis lists 5 implications of this text.
Who stands to gain
in vitro diagnostic (IVD) manufacturers developing multi-cancer blood tests; genomic sequencing companies; clinical laboratory service providers